{"id":"https://openalex.org/W2120194751","doi":"https://doi.org/10.1080/00498250210144820","title":"Pharmacokinetics and disposition of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in rat","display_name":"Pharmacokinetics and disposition of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in rat","alternate_titles":[],"publication_year":2002,"publication_date":"2002-01-01","ids":{"openalex":"https://openalex.org/W2120194751","doi":"https://doi.org/10.1080/00498250210144820","mag":"2120194751","pmid":"https://pubmed.ncbi.nlm.nih.gov/12296991"},"language":"en","primary_location":{"id":"doi:10.1080/00498250210144820","doi":"https://doi.org/10.1080/00498250210144820","is_oa":false,"landing_page_url":"https://doi.org/10.1080/00498250210144820","pdf_url":null,"source":{"id":"https://openalex.org/S48760969","display_name":"Xenobiotica","issn_l":"0049-8254","issn":["0049-8254","1366-5928"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-3"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Xenobiotica","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2120194751"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5003720055","display_name":"Ken-ichi Nezasa","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210118477","display_name":"Shionogi (Japan)","ror":"https://ror.org/01v3bqg10","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210118477"]}],"countries":["JP"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"K. Nezasa","raw_affiliation_strings":["Developmental Research Laboratories, Shionogi and Co., Ltd, 3-1-1, Futaba-cho, Toyonaka, Osaka 561-0825, Japan. kenichi.nezasa@shionogi.co.jp","Developmental Research Laboratories, Shionogi and Co., Ltd, 3-1-1, Futaba-cho, Toyonaka, Osaka 561-0825, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Developmental Research Laboratories, Shionogi and Co., Ltd, 3-1-1, Futaba-cho, Toyonaka, Osaka 561-0825, Japan. kenichi.nezasa@shionogi.co.jp","institution_ids":["https://openalex.org/I4210118477"]},{"raw_affiliation_string":"Developmental Research Laboratories, Shionogi and Co., Ltd, 3-1-1, Futaba-cho, Toyonaka, Osaka 561-0825, Japan","institution_ids":["https://openalex.org/I4210118477"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061255419","display_name":"Atsushi TAKAO","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"A. Takao","raw_affiliation_strings":["Tokai Research Laboratories, Daiichi Pure Chemicals Co., Ltd, Ibaraki, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Tokai Research Laboratories, Daiichi Pure Chemicals Co., Ltd, Ibaraki, Japan","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101806777","display_name":"Kazuhiro Kimura","orcid":"https://orcid.org/0000-0002-8683-1598","observed_orcids":["https://orcid.org/0000-0002-8683-1598"]},"institutions":[{"id":"https://openalex.org/I4210118477","display_name":"Shionogi (Japan)","ror":"https://ror.org/01v3bqg10","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210118477"]}],"countries":["JP"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"K. Kimura","raw_affiliation_strings":["Developmental Research Laboratories, Shionogi and Co., Ltd, 3-1-1, Futaba-cho, Toyonaka, Osaka 561-0825, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Developmental Research Laboratories, Shionogi and Co., Ltd, 3-1-1, Futaba-cho, Toyonaka, Osaka 561-0825, Japan","institution_ids":["https://openalex.org/I4210118477"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112089330","display_name":"Matsuo TAKAICHI","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"M. Takaichi","raw_affiliation_strings":["Tokai Research Laboratories, Daiichi Pure Chemicals Co., Ltd, Ibaraki, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Tokai Research Laboratories, Daiichi Pure Chemicals Co., Ltd, Ibaraki, Japan","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081686680","display_name":"Kazuhiro Inazawa","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210118477","display_name":"Shionogi (Japan)","ror":"https://ror.org/01v3bqg10","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210118477"]}],"countries":["JP"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"K. Inazawa","raw_affiliation_strings":["Developmental Research Laboratories, Shionogi and Co., Ltd, 3-1-1, Futaba-cho, Toyonaka, Osaka 561-0825, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Developmental Research Laboratories, Shionogi and Co., Ltd, 3-1-1, Futaba-cho, Toyonaka, Osaka 561-0825, Japan","institution_ids":["https://openalex.org/I4210118477"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5016129923","display_name":"Masahiro Koike","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"M. Koike","raw_affiliation_strings":["Tokai Research Laboratories, Daiichi Pure Chemicals Co., Ltd, Ibaraki, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Tokai Research Laboratories, Daiichi Pure Chemicals Co., Ltd, Ibaraki, Japan","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":1.02,"has_fulltext":false,"cited_by_count":58,"citation_normalized_percentile":{"value":0.70981755,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":86,"max":98},"biblio":{"volume":"32","issue":"8","first_page":"715","last_page":"727"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.6753000020980835,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.6753000020980835,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10394","display_name":"Lipoproteins and Cardiovascular Health","score":0.25099998712539673,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11618","display_name":"Cholesterol and Lipid Metabolism","score":0.031099999323487282,"subfield":{"id":"https://openalex.org/subfields/1303","display_name":"Biochemistry"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/rosuvastatin","display_name":"rosuvastatin","score":1.0},{"id":"https://openalex.org/keywords/statins","display_name":"statins","score":0.8820000290870667},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9980000257492065},{"id":"https://openalex.org/keywords/tissue-distribution","display_name":"tissue distribution","score":0.8989999890327454},{"id":"https://openalex.org/keywords/liver-accumulation","display_name":"liver accumulation","score":0.4359999895095825},{"id":"https://openalex.org/keywords/biliary-excretion","display_name":"biliary excretion","score":0.9200000166893005},{"id":"https://openalex.org/keywords/fecal-excretion","display_name":"fecal excretion","score":0.8109999895095825},{"id":"https://openalex.org/keywords/drug-metabolism","display_name":"drug metabolism","score":0.5920000076293945}],"concepts":[{"id":"https://openalex.org/C2780499067","wikidata":"https://www.wikidata.org/wiki/Q415159","display_name":"Rosuvastatin","level":2,"score":0.9647433161735535},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.7284446954727173},{"id":"https://openalex.org/C2777056448","wikidata":"https://www.wikidata.org/wiki/Q285166","display_name":"Oral administration","level":2,"score":0.6201688051223755},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.6137874126434326},{"id":"https://openalex.org/C2780026642","wikidata":"https://www.wikidata.org/wiki/Q40924","display_name":"Urine","level":2,"score":0.5989052057266235},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.5526665449142456},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5283352136611938},{"id":"https://openalex.org/C134651460","wikidata":"https://www.wikidata.org/wiki/Q3100717","display_name":"Reductase","level":3,"score":0.5228959918022156},{"id":"https://openalex.org/C10146269","wikidata":"https://www.wikidata.org/wiki/Q185557","display_name":"Excretion","level":2,"score":0.4863177239894867},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4768984317779541},{"id":"https://openalex.org/C2777320049","wikidata":"https://www.wikidata.org/wiki/Q2989497","display_name":"Hydroxymethylglutaryl-CoA reductase","level":5,"score":0.426751047372818},{"id":"https://openalex.org/C104950815","wikidata":"https://www.wikidata.org/wiki/Q415607","display_name":"HMG-CoA reductase","level":4,"score":0.32913899421691895},{"id":"https://openalex.org/C181199279","wikidata":"https://www.wikidata.org/wiki/Q8047","display_name":"Enzyme","level":2,"score":0.27005064487457275},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.21042370796203613},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.17819252610206604}],"mesh":[{"descriptor_ui":"D000068718","descriptor_name":"Rosuvastatin Calcium","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001646","descriptor_name":"Bile","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D002250","descriptor_name":"Carbon Radioisotopes","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005464","descriptor_name":"Fluorobenzenes","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D006903","descriptor_name":"Hydroxymethylglutaryl CoA Reductases","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008956","descriptor_name":"Models, Chemical","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D013449","descriptor_name":"Sulfonamides","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D013997","descriptor_name":"Time Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014018","descriptor_name":"Tissue Distribution","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017207","descriptor_name":"Rats, Sprague-Dawley","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019161","descriptor_name":"Hydroxymethylglutaryl-CoA Reductase Inhibitors","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D019540","descriptor_name":"Area Under Curve","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051381","descriptor_name":"Rats","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1080/00498250210144820","doi":"https://doi.org/10.1080/00498250210144820","is_oa":false,"landing_page_url":"https://doi.org/10.1080/00498250210144820","pdf_url":null,"source":{"id":"https://openalex.org/S48760969","display_name":"Xenobiotica","issn_l":"0049-8254","issn":["0049-8254","1366-5928"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-40","russia-white-list-3"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Xenobiotica","raw_type":"journal-article"},{"id":"pmid:12296991","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/12296991","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Xenobiotica; the fate of foreign compounds in biological systems","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9391000270843506,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320309558","display_name":"Wake Forest University","ror":"https://ror.org/0207ad724"},{"id":"https://openalex.org/F4320309809","display_name":"Cell Science Research Foundation","ror":"https://ror.org/01v3bqg10"},{"id":"https://openalex.org/F4320323316","display_name":"Shionogi","ror":"https://ror.org/01v3bqg10"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":18,"referenced_works":["https://openalex.org/W37100060","https://openalex.org/W1533066565","https://openalex.org/W1606937999","https://openalex.org/W1977783528","https://openalex.org/W1985964614","https://openalex.org/W2001143956","https://openalex.org/W2005518854","https://openalex.org/W2033511358","https://openalex.org/W2034513513","https://openalex.org/W2035975170","https://openalex.org/W2041189632","https://openalex.org/W2069447376","https://openalex.org/W2081957433","https://openalex.org/W2113799985","https://openalex.org/W2126543805","https://openalex.org/W2994468697","https://openalex.org/W3006796381","https://openalex.org/W4241761292"],"related_works":["https://openalex.org/W2022507089","https://openalex.org/W2105813268","https://openalex.org/W2033511358","https://openalex.org/W2113799985","https://openalex.org/W1977783528","https://openalex.org/W1844597293","https://openalex.org/W2945699464","https://openalex.org/W2061614515","https://openalex.org/W3119722331","https://openalex.org/W2798064831"],"abstract_inverted_index":{"1.":[0],"The":[1,106,165],"pharmacokinetics":[2],"and":[3,35,41,69,85,91,117,142,156,206],"disposition":[4],"of":[5,20,30,43,59,63,127,147,168],"rosuvastatin,":[6],"a":[7],"new":[8],"3-hydroxy-3-methylglutaryl":[9],"coenzyme":[10],"A":[11],"(HMG-CoA)":[12],"reductase":[13],"inhibitor,":[14],"were":[15,153],"investigated":[16],"following":[17],"single":[18],"administration":[19,29,80],"(14)C-rosuvastatin":[21,31],"in":[22,46,54,66,71,81,88,93,101,114,130,138,173,198,209],"the":[23,39,44,47,52,64,67,72,82,89,94,102,112,115,121,125,128,131,139,143,148,151,199,202,210,214],"Sprague-Dawley":[24],"rat.":[25,105],"2.":[26],"Following":[27],"oral":[28,79,163],"at":[32],"1,":[33],"5":[34],"25":[36,157],"mg":[37],"kg(-1),":[38],"C(max)":[40],"AUC":[42],"radioactivity":[45,60,113,129,144],"plasma":[48,152],"increased":[49],"more":[50],"than":[51,136],"increase":[53],"dose":[55,65],"ratio.":[56],"3.":[57],"Excretion":[58],"was":[61,86,133,170,207],"98.0%":[62],"faeces":[68],"0.4%":[70],"urine":[73,95],"up":[74,96,158],"to":[75,97,150,159],"168":[76],"h":[77,99,161],"after":[78,162],"intact":[83],"rat,":[84],"55.1%":[87],"bile":[90,103,116,211],"0.5%":[92],"48":[98,160],"post-dosing":[100],"duct-cannulated":[104],"unchanged":[107,215],"compound":[108],"mainly":[109,212],"accounted":[110],"for":[111],"faeces.":[118],"4.":[119],"In":[120],"tissue":[122],"distribution":[123,167],"study,":[124],"concentration":[126,145],"liver":[132,149,200],"markedly":[134],"higher":[135],"those":[137],"other":[140],"tissues,":[141],"ratios":[146],"between":[154],"8":[155],"administration.":[164],"liver-specific":[166],"rosuvastatin":[169,182,195],"similarly":[171],"recognized":[172],"whole-body":[174],"autoradiography.":[175],"5.":[176],"Metabolic":[177],"profiling":[178],"studies":[179],"indicated":[180],"that":[181,194],"would":[183],"not":[184],"be":[185],"metabolized":[186],"by":[187],"CYP":[188],"enzymes.":[189],"6.":[190],"These":[191],"results":[192],"clarified":[193],"selectively":[196],"distributed":[197],"-":[201,205],"target":[203],"organ":[204],"excreted":[208],"as":[213],"compound.":[216]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2120194751","counts_by_year":[{"year":2025,"cited_by_count":4},{"year":2024,"cited_by_count":1},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":3},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":3},{"year":2015,"cited_by_count":3},{"year":2014,"cited_by_count":5},{"year":2013,"cited_by_count":7},{"year":2012,"cited_by_count":5}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
